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ABSTRACT
PRAJA, a RING-H2 E3 ligase, is abundantly expressed in brain tissues such as
the cerebellum and frontal cortex, amongst others, and more specifically in neural
progenitor cells as well as in multiple cancers that include glioblastomas. However, the
specific role that Praja plays in neural development and gliomas remains unclear. In
this investigation, we performed bioinformatic analyses to examine Praja1 and Praja2
expression across 29 cancer types, and observed raised levels of Praja1 and Praja2 in
gliomas with an inverse relationship between Praja1 and apoptotic genes and Praja
substrates such as Smad3. We analyzed the role of Praja in the developing brain
through loss of function studies, using morpholinos targeting Praja1 in embryonic
zebrafish, and observed that Praja1 is expressed prominently in regions enriched
with neural precursor cell subtypes. Antisense Praja morpholinos resulted in multiple
embryonic defects including delayed neural development likely through increased
apoptosis. Further studies revealed high levels of Cdk1 with loss of Praja1 in TGF-β
or insulin treated cells, supporting the link between Praja1 and cell cycle regulation.
In summary, these studies underscore Praja’s role in mammalian brain development
and Praja1 deregulation may lead to gliomas possibly through the regulation of cell
cycle and/or apoptosis.

INTRODUCTION

have recently been identified as viable targets in cancer [2,
3]. Yet to date, specific populations responsive to therapy
have not been delineated for most cancer types including
glioblastomas. We identified a RING E3 ligase, PRAJA
that is highly expressed in brain tissues including the
cerebellum, cerebral cortex, occipital pole, frontal lobe,
amongst others [4]. Interestingly, Praja1 (PJA1) has been
shown to be linked to human chromosome Xq12, between
markers DXS983 and DXS1216, which is an area linked
to X-linked mental retardation (MRX) [4]. Additionally,
we have previously demonstrated that PJA1 is involved

Glioblastoma multiforme (GBM) is the most
common primary malignancy of the brain as it is highly
infiltrative and has a poor prognosis among cancers.
GBM constitutes 17% of all brain cancers, primary and
metastatic, with median survival of 14.6 months and a twoyear survival rate of 30% [1]. With current therapeutics,
improvement in patient survival is marginal, therefore
identification of new targets remains urgent. E3 ligases
www.impactjournals.com/Genes&Cancer
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in regulating tumor suppressors in the Transforming
Growth Factor-β (TGF-β) signaling pathway [5-7]. In this
investigation, to explore a potential role for PRAJA in
tumorigenesis, we conducted a genomic analysis of Praja1
(PJA1), Praja2 (PJA2) and Smad3 across 29 tumor types.
One of the most striking observations was that the greatest
amplitude in expression of PJA1 and PJA2 occurred in
glioblastomas [8], and correlated with a concomitant and
significant decrease in expression levels of Smad3, which
we have identified as a PJA1 substrate [6, 7], and as a key
receptor that regulates TGF-β signaling molecules [9, 10].
A precise sequence of genetic, biochemical, physical
and environmental factors lead to the development
of accurately placed nerve cells in the cortex, with its
dendrites, synapses and axons in a network where each
neuron functions as a part of the symphony that makes
up the brain [11]. Ubiquitination and apoptosis are
major mechanisms that are active amongst neuronal cell
precursors and neurons to modulate the population and
connectivity of the cerebral cortical neurons. For instance,
E3 ligases play a role by the degradation of the proapoptotic p53 and a few anti-apoptotic factors. Another

example is the degradation of Myc protein by the E3
ligase Huwe1, which allows expression of neurogenic
markers (Neurogenin, N-Cadherin and MAP2) normally
suppressed by Myc [12]. Here we report the expression of
PJA1 E3 ligase in embryonic brain development as well
as in TGF-β deficient Sptbn-/- mutant mice. Loss of PJA1
in a zebrafish model leads to delayed neural development,
apoptosis, as well as loss of dorsalization. Further kinases
analysis revealed the association of PJA1 with cyclindependent kinase 1 (Cdk1, cdc2) activation [13, 14],
indicating a functional pathway in cell cycle, apoptosis as
well as neural malignancies such as gliomas.

RESULTS
Bioinformatic analyses revealed increased levels
of PJA1 and PJA2 in brain malignancies
PJA1 and PJA2 share more than 80% sequence
identity of the RING finger domain at the C-terminal. To

Figure 1: Bioinformatic analyses of PJA1, PJA2 and Smad3 genetic alterations in brain tumors from the databases of
The Cancer Genome Atlas. A. PJA1 and PJA2 RNA expressions shown across 29 cancer types in TCGA databases. RNA expression
is shown to be relatively higher in gliomas and glioblastoma multiforme. B. Cancer histogram analysis of genetic alterations of PJA1 and
PJA2 in 36 cancer types in TCGA databases. C. Analyses of PJA1, PJA2, and Smad3 expression in the TCGA merged cohort of LGG
and GBM dataset TCGA Brain Lower Grade Glioma (LGG) dataset (n = 794). D. Analyses of PJA1, PJA2, and Smad3 genetic alterations
in the TCGA LGG dataset (n = 530). Genetic alterations of PJA1 frequently co-occur with Smad3 alterations (p = 0.001) whereas PJA2
alterations are mutually exclusive with Smad3 alterations (p = 0.029). E. Association of PJA1 with Smad3 and Sptbn1 was examined by
co-immunoprecipitation with anti-PJA or anti-SPTBN1 in cells transfected with indicated plasmids and the binding of PJA1 with Smad3
and SPTBN1 was determined by anti-V5.
www.impactjournals.com/Genes&Cancer
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better understand their roles in brain development and
malignancies, we performed bioinformatic analyses of
the expression of PJA1 and PJA2 across 29 cancers in
the TCGA databases and found that both PJA1 and PJA2
are highly expressed in brain malignancies including
Glioblastoma (GBM) and Gliomas (Figure 1A) [8]. The
same results were observed in the TCGA adrenocortical
carcinoma study and an advanced prostate cancer study
[15] (Supplementary Figure 1). We further analyzed
genetic alterations of PJA1 and PJA2 that include copy
number (CPN) gain, amplification, shallow deletion, deep
deletion and mutations in 36 different cancer types. CPN
gain and amplification are the most common alterations of
these genes across all cancer types analyzed (Figure 1B),
suggesting potential oncogenic roles of PJA in cancers. In
a TCGA study with merged cohort of Low Grade Glioma
(LGG) and GBM [8], PJA1, PJA2 Smad3 and altered in
9%, 4% and 14% of samples, respectively (Figure 1C).
Similarly, we observed increased expression of PJA1 and
PJA2 in 20% and 10%, respectively, of the 530 samples
from 516 sequenced patients in a TCGA study on LGG

(Figure 1D). While CPN gain or amplification is frequently
observed in PJA1 and PJA2, Smad3 is more frequently
downregulated or deleted (Figure 1C-1D). Interestingly,
genetic alterations of PJA1 but not PJA2 frequently cooccur with Smad3 alterations, which is consistent with
our previous findings that PJA1 directly binds to TGF-β
signaling components, Smad3 and its adaptor SPTBN1
(Figure 1E) [7].

PJA1 is expressed in brain regions enriched with
neuronal precursor cells
Given that PJA1 is highly expressed in brain
malignancies, we then examined PJA1 expression in
brain tissues. Northern blot analysis of PJA1 mRNA
demonstrates a 2.7 kb transcript in human brain tissues and
is found to be more abundantly expressed in the cerebral
cortex, occipital lobe, frontal lobe, cerebellum and caudate
nucleus. Relatively low abundance of the PJA1 transcript
is seen in the brainstem structures, such as the medulla,
spinal cord, corpus callosum and substantia nigra (Figure

Figure 2: PJA1 expression in brain. A. Northern blot analysis of PJA1 expression in human brain tissues. Cerebral cortex, occipital,

frontal lobes and caudate nucleus demonstrate prominent mRNA for PJA1. B. Immunoperoxidase labeling of PJA1 in E12 mouse embryo
forebrain marginal zone (MZ) (i) and mantle zone (ii). The left panel (i) shows Cajal-Retzius cells of the marginal layer labeled (arrows)
while the right panel (ii) shows fibrillary label extending from cells in the mantle zone. C. Immunoperoxidase labeling of PJA1 in E12
mouse embryo midbrain (i) and cerebellum (ii). PJA1 is expressed in the SVZ cells and in developing midbrain nuclei (arrows). D. PJA1
expression compared in E12 forebrain of wild type (i-ii) and mutant Sptbn1-/- mice (iii, iv). Left panels are (i, iii) at 20X magnification; right
panels (ii, iv) are at 40X magnification. PJA1 is expressed in SVZ cells and appears to be more widely distributed in embryonic brain of
mutant Sptbn1-/- mice. E. Immuno-histochemical analysis of H & E staining of mouse embryos reveals the fore brain development defect
in mutant Sptbn1-/- mice.
www.impactjournals.com/Genes&Cancer
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2A). Additional immunohistochemistry (IHC) staining of
PJA1 in normal brain revealed that PJA1 is expressed in
the hindbrain, midbrain, forebrain, cerebellum, and basal
ganglia of E12 and E15 (12 and 15 days post-coitum)
embryonic mice (Figure 2B-2C). Earlier, day 11.5 embryos
were found to express PJA1, in the Subventricular Zone
(SVZ) cells. PJA1 label is observed in cells that are
identified as Cajal-Retzius cells by morphology and
location [16], in the outer layer (marginal zone) of the E12
developing cortex in mouse embryo brain (Figure 2B, i).
PJA1 label is also demonstrated in the cells of the SVZ in
E12 forebrain cortex (Figure 2C ii). In both cell types, the
label appears perinuclear and polarized. In the developing
forebrain cortex, PJA1 label also appears in fibrillar form
extending from cells with larger nuclei (Figure 2B ii).
This fibrillary appearance is also observed with the TGF-β
adaptor, SPTBN1 labels at the same embryonic stage of
mouse brain development. In the midbrain, cerebellum,
and hindbrain, PJA1 is expressed in the cytoplasm of
scattered cells among the developing midbrain and
brainstem nuclear groups (Figure 2C i). However, SVZ
cells continue to express PJA1 (Figure 2C ii).
Consistently, PJA1 IHC in different areas of E12
brain demonstrates that PJA1 is normally expressed in the
SVZ that is enriched with neuronal precursor cells [17] and
the collection of hindbrain nuclei in E12 embryonic brain
of wild type mouse embryo (Figure 1D i, ii). Interestingly,
in contrast to that of wild type mice, PJA1 expression is

more widely expressed in the developing brain of TGF-β
deficient (Sptbn1-/-) mutant mice. Additionally, PJA1
expression appears to be strongly diffused in Sptbn1-/mutant mice compared with that in wild type SVZ cells
(Figure 1D iii, iv). It is noteworthy that the mutant embryo
brain exhibits multiple fore brain developmental defect
including abnormal brain vesicles, further suggesting
an important role of PJA1 in normal brain development
(Figure 1E) [10, 18].

Loss of PJA1 leads to developmental defect
in zebrafish embryonic brain with increased
apoptosis
We also detected normal PJA1 expression in
zebrafish embryo (Figure 3A) using whole mount in situ
hybridization. PJA1 is expressed in the yolk sac and is
evenly and strongly expressed along the entire length of
the embryo, with a steep ventral-dorsal gradient such that
high ventral expression abruptly drops to undetectable
levels in the dorsal-most 20-30% of the embryo. By 28
hours post-fertilization (hpf), the PJA1 expression pattern
becomes more refined and restricted to specific tissues. In
the brain, PJA1 is strongly expressed throughout the basal
plate, while expression in the alar plate is predominantly
restricted to the ventricular zones. In addition, PJA1 is
expressed in the head mesenchyme, intestinal and vascular

Figure 3: Apoptosis dramatically increases in zebrafish embryos upon PJA1 knockdown. A. PJA1 mRNA expression was

determined by whole-mount in situ hybridization in developing embryos. PJA1 mRNA is expressed in the yolk and ventral side of the
embryo at the 13 somite stage (i) and in intestinal and vascular tissues at 28 hour post-fertilization (hpf) (ii). B. Developmental defects were
observed in zebrafish embryos injected with 4ng or 8ng of antisense PJA1 morpholino oligonucleotides (MO) but not in embryos injected
with same dose of control MO. C. Apoptosis was visualized by acridine orange staining in live embryos, where apoptotic cells are indicated
by green fluorescence. Compared to that of the control MO injected embryos at 24 hpf. D. injection of PJA1 MOs severely disrupted
embryogenesis (v) and resulted in high levels of apoptosis (vi). Red squares indicate the embryonic brain of zebrafish.
www.impactjournals.com/Genes&Cancer
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structures of the trunk and tail, and mesendodermal
tissues near the yolk sac (Figure 3A), indicating that
PJA1 may play a particularly important role in GI organ
development.
To test our hypothesis that PJA1 is required for
normal brain development, translation-blocking antisense
PJA1 Morpholino oligonucleotides (MO) were injected
into single-cell stage zebrafish embryos to knock down
PJA1 that is normally expressed in zebrafish embryos
(Figure 3A). As we expected, morpholino-mediated
PJA1 knockdown results in multiple developmental
defects throughout the embryo (Figure 3B) including
reduced brain development, shortened and deformed tail,
abnormal notochord, and loss of the chevron shape of the
somites. The overall appearance of the PJA1 MO injected
embryos (Praja1 morphants), in comparison to control
MO injected embryos, is that they have smaller head size
with curved bodies and tails (Figure 3B-3C). Further, we
found increased apoptosis visualized by acridine orange
staining throughout the somitogenesis period in PJA1
MO injected embryos relative to control MO injected
embryos. By 24 hpf, when somitogenesis is complete and

most organ primordia have formed, apoptosis remains
high, specifically in the head (Figure 3C iv, vi); by 36 hpf,
apoptosis in PJA1 morphants starts to level off; and by 48
hpf is only slightly higher than that in control embryos.
These studies indicate that PJA1 is important for inhibiting
apoptosis during zebrafish embryogenesis.

PJA1 protects cells from apoptosis
To further examine the potential mechanism for
the developmental defects caused by PJA1 inhibition
and determine the role of PJA1 in cellular apoptosis, we
introduced RING domain-deleted mutant PJA1 (ΔRING
mut) in cells. This mutant was identified as a loss-offunction mutant by our group in the regulation of TGF-β
signaling through Smad3 and its adaptor, SPTBN1 [7,
19, 20]. Through Annexin V staining, we found that
expression of PJA1 mutant in cells results in three-fold
increase of apoptosis (Figure 4A). In addition, knockdown
of PJA1 by shRNA in HepG2 cells leads to increased cell
apoptosis as determined by increased PARP expression
as well as increased Caspase 3 and cleavage of Caspase3

Figure 4: PJA1 defects lead to increased cell apoptosis. A. Apoptotic response to Cisplatin of the Huh7 cells that express a RING

domain-deleted PJA1 mutant. The expression of the inactive PJA1 mutant (ΔRING mut) causes more than a three-fold increase in the
percentage of apoptotic cells. B. Apoptotic response of HepG2 cells with reduced PJA1 expression after treatment with Sorafenib. PJA1
knockdown demonstrated that Caspase3 and PARP cleavage were significantly elevated compared to control with a dose-dependent pattern.
C. The percentage of apoptotic cells is consequently higher in PJA1 knockdown and Sorafenib treatment. D. Negative Pearson’s correlation
between PJA1 and apoptotic genes in TCGA LGG dataset.
www.impactjournals.com/Genes&Cancer
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(Figure 4B). To examine whether kinases are required
for apoptosis induced by PJA1 defect, we treated cell
with Sorafenib, a tyrosine kinase inhibitor. Interestingly,
Sorafenib synergizes with PJA1 knockdown to increase
cell apoptosis in a dose-dependent manner (Figure 4B4C). Consistently, analysis of co-expression of genes with
PJA1 revealed a negative Pearson’s correlation between
PJA1 and several apoptotic genes, including Bax and Bak
as well as caspases 6, 8, 10, 1, 4 and 7 in LGG (Figure
4D). All these data strongly support the anti-apoptotic
effect of PJA1.

both TGF-β and insulin treated cells transfected with PJA
mut compared with cells transfected with PJA wild type
(Figure 5, Supplementary Tables 1-4), indicating that Cdk1
activation is negatively regulated by PJA1. Our study is
in line with previous findings showed that aberrant Cdk1
activation has been associated with neuronal cell apoptosis
and Cdk1 is critical to brain development [13, 14, 21-23].
In addition to Cdk1 activation, insulin activating through
insulin receptors induces activation of MEK/ERK and
Akt signaling pathway in cells expressing PJA1 mutant,
suggesting a negative regulation of these pathways by
PJA1 as well.

PJA1 is associated with CDK1 activation

DISCUSSION

To further explore the mechanism underlying PJA1mediated brain development, we performed KinetworksTM
phosphor-site broad coverage pathway screen in cells
transfected with either wild type PJA1 or PJA1 ΔRING
mut, a loss-of-function mutant [7]. Profiles of activated
kinases, induced by either TGF-β or insulin treatment,
were examined through band visualization via ECL and
quantification (Figure 5A-5D). We observed consistently a
two-fold induction of Cdk1 phosphorylation at T14/Y15 in

In this study, we explored the role of praja1 (PJA1)
in brain development and found that PJA1 protects cells
from apoptosis and is required for the normal embryonic
development. In addition, loss of PJA1 leads to hyperactivation of Cdk1 and thereby induces cell apoptosis
during early embryogenesis possibly through cell cycle
mitosis stress as Cdk1 is known to interact with cylin
B1 to control the progression of cell cycle from G2- to
M-phase. Aberrant Cdk1 activation has been associated

Figure 5: Elevated Cdk1 activity is associated with loss of PJA1. A. Increased Cdk1 phosphorylation in cells transfected with

PJA mutant. Protein phosphorylation visualized by ECL show increased phosphorylation activity in Cdk1 (Lane 7) in TGF-β treated
cells transfected with PJA1 mutant (ΔRING mut) (right) compared to that in cells transfected with wild type PJA1 setting (left). The
quantification results of bands were showed in the top table. B. Bar graph shows the quantification of the phosphorylation of each kinase
and their respective sites as indicated in A. C. Increased phosphorylation activity in Cdk1 (Lane 7) in insulin treated cells transfected with
PJA1 mutant (ΔRING mut) (right) compared to cells transfected with wild type PJA1 setting (left). The quantification results of bands were
shown in the top table. D. Bar graph shows the quantification of the phosphorylation of each kinase and their respective sites as indicated
in C.
www.impactjournals.com/Genes&Cancer
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with cell apoptosis [13, 14, 21-24].
Our integrated genomic analyses of LGG and
GBM indicate a potential new role for PJA1 in gliomas,
potentially through its preciously demonstrated
ubiquitination of the Smad3- likely reflecting the TGF-β
tumor suppressor role in this cancer [5-7, 9, 10, 18].
Interestingly, although we observed PJA2 mutations in
brain cancer [8], we found no mutations in PJA1, only
alterations leading to raised PJA1 expression. Further
insight into PJA1 was obtained by examining its coexpression with apoptotic genes. Pearson’s correlation
analysis revealed a negative moderate relationship
between PJA1 and these apoptotic genes, which suggest
an negative anti-apoptotic role of PJA1. Indeed, PJA1
knockdown leads to high levels of apoptosis. This prosurvival, anti-apoptotic role for PJA1 lends further support
to the notion that it may be function as an oncogene.
The study suggests important functions for PJA1
in the neural development as well. The appearance of
PJA1 label in the region enriched with neural progenitors
(SVZ cells) without labeling radial glial cells and other
progenitor cells, characterizes a subset of progenitor cells
by phenotype. Cajal Retzius cells and subventricular zone
cells are predominant early neural progenitor cells of
embryonic brain. Usually also confirmed by double label
with ‘Reelin’ [25]- Cajal Retzius cells are located in the
outer zone of the developing cortex, and have been shown
to differentiate into neuronal cell phenotype [26]. SVZ
cells on the other hand are nestin [27] positive, musashi-1
[28] positive, and give rise to radial glial cells that in turn
populate the embryonic forebrain cortex with neuroblasts.
Loss of PJA1 expression in zebrafish led to
apoptosis, resulting in delayed neural development. The
upregulation of Cdk1 in loss of PJA1 function suggests
a key role of loss of PJA1 expression in the irregularities
of Cdk1/cyclin B mitotic cascade that instigates hyperphosphorylation of neuronal proteins and neuronal
apoptosis. Interestingly, previous research has marked
that Cdk1/cyclin B overexpression in gliomas, marking
it as a potential oncogene and highlighting the various
apoptotic roles that Cdk1/cyclin B plays contingent upon
Praja expression [13, 14].
PJA1’s role in neural development and gliogenesis
can be understood through its structural and functional
homolog PJA2 and its role as an A-kinase-anchoring
protein (AKAP), which anchors protein kinase A1 (PKA)
to specific intracellular sites and is involved in protein
sorting at axosomatic synapses [29]. PKA and cAMP also
serve roles in axon formation as impeding PKA anchored
to AKAPs increased cAMP gradient in neurons which led
to enhanced axon elongation [30]. PJA1 appears to play a
multifunctional role in neuronal development. The MAGE
(melanoma antigen) member NRAGE (neurotrophin
receptor associated MAGE famohomologue), also
known as Dlxin-1 in mouse and MAGE-D1 in human
[31], is directly targeted by PJA1 for ubiquitination and
www.impactjournals.com/Genes&Cancer

subsequent degradation [32]. NRAGE deletion impedes
BMP regulated neural developmental apoptosis of
sympathetic neurons [33]. In addition, NRAGE has also
been found to inhibits several AKAPs in conjunction
with p75 neurotrophin receptor (p75NTR) [34]. A recent
study found that PJA2 induces ubiquitin/proteasomal
degradation of Mob1 (Mps one binder 1), a kinase
regulator of the Hippo cascade, promoting glioblastoma
formation [35]. Collectively, our studies demonstrate
an important role for Praja in neural development, and
gliomas, providing a basis for future investigations into
targeting Praja in gliomas, that are lethal cancers.

MATERIALS AND METHODS
Bioinformatics analysis
The Cancer Genome Atlas (TCGA) database from
cBioportal was utilized to examine transcriptomic and
genomic alterations of Praja1 (PJA1), Praja2 (PJA2), and
Smad3 (SMAD3) (http://www.cbioportal.org/). Genomic
profiles were chosen based on our studies of interest
including TCGA Brain Lower Grade Glioma (LGG),
consisting of 530 samples from 516 patients, and TCGA
Merged cohort of LGG and Glioblastoma Multiforme
(GBM), consisting of 794 samples. Mutations, putative
copy number alterations from GISTIC, mRNA expression
z-scores (RNA Seq V2 RSem; z-score threshold ± 2),
and protein expression z-scores (z-score threshold ± 2)
were chosen out of the profiles for TCGA Lower Grade
Glioma and TCGA merged cohort of LGG and GBM.
PJA1 and PJA2 expression were first analyzed across
all cancer types. Oncoquery language was utilized for
the selection of samples with gain of function (GAIN),
amplification (AMP), mRNA upregulation (EXP > = 1.5),
or mutations in PJA1 or PJA2 (MUT), as well as deletion
or loss (HETLOSS, HOMEDEL), mRNA downregulation
(EXP < = -1.5), or mutation in Smad3 when observing
TCGA Lower Grade Glioma. Following the completion
and submission of the outlined query, the oncoprint,
mutations, mutual exclusivities, and mRNA coexpression
tabs were chosen and their results were individually
recorded. Specifically, when examining the oncoprint
results, the percentage of patient samples with alterations
in the queried genes and whether those various samples
increased expression of the genes (i.e. amplification,
gain, or mRNA upregulation) or decreased expression
(i.e. deletion, loss, or mRNA downregulation) was noted
and observed. Subsequently, we attempted to identify
mutations in PJA1 and PJA2 in these malignancies,
thereby juxtaposing the results and structures of the
two genes. While examining the mutual exclusivity or
co-expression of PJA1, PJA2, and Smad3 in the TCGA
Lower Grade Glioma dataset, the statistical significance of
these relationships was noted. Additionally, while utilizing
646
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mRNA co- expression from the TCGA Lower Grade
Glioma dataset, Pearson’s correlation between PJA1 and
genes (Caspases 1, 4, 7, 6, 8, 10) implicated in apoptosis
were noted.

overnight at 4°C in humidor with primary antibody diluted
to 2.5-5 μg/ml in 1x PBS containing 1 mg/ml BSA and
0.05% Triton X-100. All subsequent steps were done at
room temperature, including four 5-min rinses with 1x
PBS containing 1% goat serum after each successive
step. Sections were incubated with peroxidase-conjugated
goat anti-rabbit antibody (Jackson Immunoresearch
Laboratories, West Grove, PA) that was diluted in 0.05M
PBS in 1% serum for 30 min. After rinses, 200-500 μl
of the insoluble peroxidase substrate DAB (Sigma Fast)
was added to cover the entire tissue on the slide. Color
development was monitored under the microscope,
and then slides were rinsed for 2 min in distilled water.
Counterstaining was then performed with Harris’s
hematoxylin solution (Sigma) (modified) for 1 min,
followed by a rinse in distilled water for 5 min. Sections
were dehydrated by passage through graded alcohol
concentrations and xylene. The coverslips were mounted
using DPX (Fluka Labs).

Northern blot analysis
Northern blots with 2 μg poly-A(+) mRNA
from human brain (Clontech, USA) were probed
with 32P-labeled Praja Clone CH7 [5] insert antisense
strand using ExpressHyb hybridization solution
(Clontech, USA) at 68oC. They were washed according
to the manufacturer’s instructions and subjected to
autoradiography. A 32P-labeled β-actin probe supplied
with the Northern blots was used as a control to confirm
that normalized RNA levels were present in each lane
(Clontech).

Embryonic tissue preparation

Morpholino injection in zebrafish embryos

129SvEv/Black Swiss Mice were used following
an institutionally approved animal protocol in accordance
with the requirements and recommendations of the NIH
“Guide for the Care and Use of Laboratory Animals.” The
age of the embryos was determined by post-appearance of
the vaginal plug (day 0). Noon of this day was considered
0.5 days of gestation post-coitus (p.c). The embryos
were dissected at transitional times between days of 9.5
and 14.5 p.c. The identification and isolation of embryos
were carried out under an operative microscope. The
specimens were fixed in FEA fixative (4% formaldehyde,
85% ethanol and 5% glacial acetic acid) and embedded
in paraffin [36]. The sections, 8-15 μM thick, were cut in
the longitudinal or transverse planes using a microtome
(Reichert-Jung, USA).

Morpholinos were synthesized and purchased
from Gene Tools (http://www.gene-tools.com/). A stock
solution of 10μg/μl was prepared by dissolving the
lyophilized powder in twice-distilled water. The stock
solution was diluted to a working concentration of 2μg/μl
in 1× Danieau’s solution. Freshly laid zebrafish embryos
were collected and placed into embryo culture medium
and transferred onto an agarose platform. 4ng or 8ng of
morpholinos targeting PJA1 or control mopholinos was
injected in the yolk of embryos. Microinjection was
performed using a Nanoject injector II.

Praja function and loss of function proteomics

Immunohistochemical staining

Cultured cells transfected with wild type PJA1
or PJA1 ΔRING mut were treated with either TGF-β
(100pm) for 30min or insulin (100ng/ml) for 30min
after 5h starvation. Then cells were lysed with RIPA
lysis buffer supplemented with phosphatase and protease
inhibitors. Protein concentrations were determined by
Bio-Rad Bradford assay prior KinetworksTM phosphor-site
broad coverage pathway screen (Kinexus Bioinformatics
Corporation). Protein phosphorylation activities were
analyzed, including the combination of both analytical
techniques such as immunoblotting, protein visualization
through enhanced chemiluminescence (ECL), and gel
electrophoresis, as well as assorted methodologies. Thus,
the target kinases including Src, Erk1, Erk2, Jun, Cdc2,
Akt1, FAK, MAPK, MEK1, Rb, ERK2/Hu, and PKR were
determined by the KCPS-1.0 screen. Through the process,
an adequate reading of the quantities was observed over a
2000-fold linear range.

An indirect immunoperoxidase procedure was
used for immunohistochemical localization of Sptbn1
and PJA1 protein in brain tissues of mouse embryos.
Antibody to a peptide corresponding to amino acids 145149 (CLRRKYRSREQPQS) of PJA1 was produced in
rabbit, and used to detect Praja by immunohistochemical
labeling [5]. For β2SP, the primary antibody used was
rabbit antimouse EL-1 (against N-terminal aminoacids
2-14, ELQRTSSVSGPLS) as described previously [7,
19, 20]. Sections (8 μM) were treated with xylene to
remove paraffin, and the tissue was dehydrated by placing
it stepwise into graded higher concentrated alcohol and
rinsed in 1x phosphate-buffered saline (PBS). Endogenous
peroxidase was quenched using 3% hydrogen peroxide
(Sigma). Non-specific binding sites were blocked with
1x PBS containing 5% goat serum and 1 mg/ml bovine
serum albumin (BSA). The sections were incubated
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